Taiwan · Delayed Price · Currency is TWD InnoPharmax Statistics
Total Valuation
InnoPharmax has a market cap or net worth of TWD 1.74 billion. The enterprise value is 1.52 billion.
| Market Cap | 1.74B |
| Enterprise Value | 1.52B |
Important Dates
The next estimated earnings date is Friday, April 17, 2026.
| Earnings Date | Apr 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
InnoPharmax has 107.58 million shares outstanding. The number of shares has increased by 9.16% in one year.
| Current Share Class | 107.58M |
| Shares Outstanding | 107.58M |
| Shares Change (YoY) | +9.16% |
| Shares Change (QoQ) | +7.62% |
| Owned by Insiders (%) | 1.86% |
| Owned by Institutions (%) | 4.43% |
| Float | 90.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 31.25 |
| PB Ratio | 3.15 |
| P/TBV Ratio | 3.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -14.20 |
| EV / Sales | 27.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -15.20 |
Financial Position
The company has a current ratio of 6.80, with a Debt / Equity ratio of 0.04.
| Current Ratio | 6.80 |
| Quick Ratio | 5.83 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.20 |
| Interest Coverage | -261.52 |
Financial Efficiency
Return on equity (ROE) is -21.68% and return on invested capital (ROIC) is -12.10%.
| Return on Equity (ROE) | -21.68% |
| Return on Assets (ROA) | -11.54% |
| Return on Invested Capital (ROIC) | -12.10% |
| Return on Capital Employed (ROCE) | -17.92% |
| Revenue Per Employee | 1.69M |
| Profits Per Employee | -3.24M |
| Employee Count | 33 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 1.71 |
Taxes
In the past 12 months, InnoPharmax has paid 2.32 million in taxes.
| Income Tax | 2.32M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +0.31% in the last 52 weeks. The beta is -0.04, so InnoPharmax's price volatility has been lower than the market average.
| Beta (5Y) | -0.04 |
| 52-Week Price Change | +0.31% |
| 50-Day Moving Average | 17.39 |
| 200-Day Moving Average | 17.91 |
| Relative Strength Index (RSI) | 40.43 |
| Average Volume (20 Days) | 276,890 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoPharmax had revenue of TWD 55.77 million and -106.95 million in losses. Loss per share was -1.03.
| Revenue | 55.77M |
| Gross Profit | 17.45M |
| Operating Income | -99.12M |
| Pretax Income | -104.63M |
| Net Income | -106.95M |
| EBITDA | -97.22M |
| EBIT | -99.12M |
| Loss Per Share | -1.03 |
Balance Sheet
The company has 243.56 million in cash and 19.61 million in debt, with a net cash position of 223.95 million or 2.08 per share.
| Cash & Cash Equivalents | 243.56M |
| Total Debt | 19.61M |
| Net Cash | 223.95M |
| Net Cash Per Share | 2.08 |
| Equity (Book Value) | 552.96M |
| Book Value Per Share | 5.14 |
| Working Capital | 248.75M |
Cash Flow
In the last 12 months, operating cash flow was -99.42 million and capital expenditures -527,000, giving a free cash flow of -99.95 million.
| Operating Cash Flow | -99.42M |
| Capital Expenditures | -527,000 |
| Free Cash Flow | -99.95M |
| FCF Per Share | -0.93 |
Margins
Gross margin is 31.28%, with operating and profit margins of -177.71% and -191.76%.
| Gross Margin | 31.28% |
| Operating Margin | -177.71% |
| Pretax Margin | -187.59% |
| Profit Margin | -191.76% |
| EBITDA Margin | -174.31% |
| EBIT Margin | -177.71% |
| FCF Margin | n/a |
Dividends & Yields
InnoPharmax does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.16% |
| Shareholder Yield | -9.16% |
| Earnings Yield | -6.14% |
| FCF Yield | -5.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
InnoPharmax has an Altman Z-Score of 24.09 and a Piotroski F-Score of 2.
| Altman Z-Score | 24.09 |
| Piotroski F-Score | 2 |